NASDAQ
41.03USD
0.00 (0.00%)
We have scored 15 news catalysts on Apellis Pharmaceuticals, Inc. (APLS) over the past 12 months. The biggest single-day move next to one of them came Jan 17, 2026, when APLS closed −2.9%: “Is Apellis Pharmaceuticals' FDA Win Just the Beginning?”. Coverage across the window leans positive (average ticker sentiment +0.21). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.3B
P/E
—
EPS
—
Beta
-0.25
52W range
16.61-41.14
Day range
41.03–41.05
Open
41.05
Prev close
41.03
Volume
28.6M
Avg volume
6.4M
Dividend
0.00
IPO
2017-11-09
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Apellis Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for APLS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
